SCHEMBL26424718

SCHEMBL26424718

CC(C)(C)c1ccc(C(=O)N2CC3(CCC3)C2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.62
KMT2A Q03164 6/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
ALDH1A1 P00352 3/20 0.62
HTT P42858 2/20 0.62
HPGD P15428 3/20 0.56
ALOX15 P16050 1/20 0.56
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 1/20 0.47
MITF O75030 1/20 0.47
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CNR1 P21554 2/20 0.45
CNR2 P34972 2/20 0.45
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17886686 0.87 HPGD (0.68) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL17886789 0.87 HPGD (0.65) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL17886790 0.85 NAMPT (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL15317670 0.85 CYP3A4 (0.65) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL17886683 0.84 MEN1 (0.58) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL15317729 0.83 MEN1 (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL19226561 0.83 HPGD (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL17886684 0.82 HPGD (0.62) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL15317726 0.82 SMN1; SMN2 (0.59) MEN1KMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL18216826 0.82 MEN1 (0.63) MEN1KMT2ASMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130909-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2023-04-27 US disclosed
US-9873709-B2 Triazolopyridine compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2018-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130909-A1 HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF WEE2, WEE1, HK1 MEN1 929/4885KMT2A 3655/4885SMN1; SMN2 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.